On Aug 21, 2025, Abbvie announced that positive results from study 1 of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of RINVOQ® (Upadacitinib) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline
Updated on: September 04,2025
0